167. Marfan syndrome Clinical trials / Disease details

Clinical trials : 21 / Drugs : 40 - (DrugBank : 11) / Drug target genes : 10 - Drug target pathways : 50

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01295047 (ClinicalTrials.gov)	July 2006	11/2/2011	Comparison of Medical Therapies in Marfan Syndrome.	Effects of Atenolol, Perindopril and Verapamil on Haemodynamic and Vascular Function in Marfan Syndrome - A Randomised Double-Blind Crossover Trial	Marfan Syndrome	Drug: Atenolol;Drug: VERAPAMIL;Drug: Perindopril	Cardiff University	NULL	Completed	16 Years	60 Years	Both	18	Phase 4	United Kingdom
2	EUCTR2005-000749-13-GB (EUCTR)	30/07/2005	20/06/2005	A Randomised Double-Blind Trial of Medical Treatment In Marfan Syndrome.	A Randomised Double-Blind Trial of Medical Treatment In Marfan Syndrome.	Marfan Syndrome	Trade Name: Atenolol Product Name: Atenolol Product Code: N/A INN or Proposed INN: N/A Other descriptive name: N/A Trade Name: Coversyl Product Name: Coversyl Product Code: N/A INN or Proposed INN: N/A Other descriptive name: PERINDOPRIL Trade Name: Verapamil Product Name: Verapamil SR Product Code: N/A INN or Proposed INN: N/A Other descriptive name: N/A	Cardiff University	NULL	Not Recruiting			Female: yes Male: yes	60	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	United Kingdom
3	NCT00485368 (ClinicalTrials.gov)	January 2004	11/6/2007	Angiotensin Converting Enzyme Inhibitors in Marfan Syndrome	The Effect of an Angiotensin Converting Enzyme Inhibitor on Aortic Wall Properties in Patients With Marfan Syndrome.	Marfan Syndrome	Drug: Coversyl (perindopril)	Bayside Health	Baker Heart Research Institute;The Alfred	Completed	18 Years	40 Years	Both	17	Phase 3	NULL